<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200701047976N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-07-14</date_registration>
      <primary_sponsor>Shiraz University of Medical Sciences</primary_sponsor>
      <public_title>Effect of Hypochlorite Sodium 0.005% in treatment of Acne</public_title>
      <acronym></acronym>
      <scientific_title>Hypochlorite Sodium 0.005% versus placebo in treatment of mild to moderate Acne; A randomized double blind clinical control</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-07-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>40</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/49339</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: We used block randomization method. Our sample includes 40 patients which was divided into 10 blocks with 4 patients in each one.
With random number table, our sample was divided into A and B groups and the data was written on the paper and randomizatin was done by random number table manually. Group A received Hypochlorite sodium 0.005% on the right side of their face and group B received that on the left side of their face; concurrently, group A received placebo on the left side of their face and group B received that on the right side of their face, Blinding description: Although Hypochlorite Sodium and placebo(distilled water) were both put into the same white bottles; each bottle has specific code showing its content. Only the pharmacist is aware about these codes. During study, both dermatologist and patients were blind about using Hypochlorite sodium and placebo on each side of patients' faces.</study_design>
      <phase>2-3</phase>
      <hc_freetext>Acne Vulgaris.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Solution of Hypochlorite sodium 0.005% was prepared by pharmacist from Hypochlorite sodium 6%. In this study, the concentration of solution was determined according to the formulation used in previous studies. On the other hand, higher concentrations increase the possibility of skin damage. Although Hypochlorite sodium and placebo(distilled water) were both put into the same white bottles; each bottle has specific code showing its content. Only the pharmacist is aware about these codes. The patients received Hypochlorite sodium 0.005% administered topically on the right or left side of their face three times a day for one month. Hypochlorite sodium 0.005% was applied randomly on each side of the patients' faces. The patients were not aware of the type of solution (placebo or Hypochlorite sodium 0.005%) applied for them.In addition to patients, dermatologist and the recorder person were both blind about the solution applied for each side of  patient's face. Intervention 2: Control group: The patients received placebo(distilled water)administered topically on the right or left side of their faces three times a day for one month.The placebo was applied randomly on each side of the patients' faces. The patients were not aware of the type of solution (placebo or Hypochlorite sodium 0.005%) applied for them.In addition to patients, dermatologist and the recorder person were both blind about the solution applied for each side of  patient's face.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no more information.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Maryam Hadibarhaghtalab</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Maryam Barhaghtalab (Seifi), 2nd Floor, 143 Plaque, Zanbagh 9 Alley, Farhangshahr Blvd</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7137954999</zip>
        <telephone>+98 71 3622 3919</telephone>
        <email>Maryam_hadibarhaghtalab@yahoo.com</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Maryam Hadibarhaghtalab</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Maryam Barhaghtalab (Seifi), 2nd Floor, 143 Plaque, Zanbagh 9 Alley, Farhangshahr Blvd</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7137954999</zip>
        <telephone>+98 71 3622 3919</telephone>
        <email>Maryam_hadibarhaghtalab@yahoo.com</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients with mild to moderate Acne Vulgaris diagnosed by dermatologist</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patients with symptoms such as secondary Acne caused by lactation
Dermatology condition in addition to Acne
Patients who had taken drugs such as Isotretinoin or systemic/topical antibiotics within the last two months
Allergy to Hypochlorite Sodium</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>L70.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Acne vulgaris</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Solution of Hypochlorite sodium 0.005% was prepared by pharmacist from Hypochlorite sodium 6%. In this study, the concentration of solution was determined according to the formulation used in previous studies. On the other hand, higher concentrations increase the possibility of skin damage. Although Hypochlorite sodium and placebo(distilled water) were both put into the same white bottles; each bottle has specific code showing its content. Only the pharmacist is aware about these codes. The patients received Hypochlorite sodium 0.005% administered topically on the right or left side of their face three times a day for one month. Hypochlorite sodium 0.005% was applied randomly on each side of the patients' faces. The patients were not aware of the type of solution (placebo or Hypochlorite sodium 0.005%) applied for them.In addition to patients, dermatologist and the recorder person were both blind about the solution applied for each side of  patient's face.</i_keyword>
      <i_keyword>Control group: The patients received placebo(distilled water)administered topically on the right or left side of their faces three times a day for one month.The placebo was applied randomly on each side of the patients' faces. The patients were not aware of the type of solution (placebo or Hypochlorite sodium 0.005%) applied for them.In addition to patients, dermatologist and the recorder person were both blind about the solution applied for each side of  patient's face.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Evaluation of Acne remission on the basis of changes in the number of Papules and Pustules. Timepoint: Initiation of study(before starting the treatment), 14 days and 28 days after starting the treatment. Method of measurement: Counting the number of Papules and Pustules.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shiraz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2018-12-31</approval_date>
        <contact_name>Ethics committee of Shiraz University of Medical Sciences</contact_name>
        <contact_address>School medicine of Shiraz, Emam Hosein Square, Zand Blvd Shiraz Fars Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
